Follow The Filings

CRSP position history

The shares of Crispr Therapeutics (CRSP) that Palo Alto Investors LP reported in each quarter’s 13F.

Equity, NAMEN AKT

Shares held by quarter

New Add Reduce Exit

  1. 2025 Q2: 44,625 shares, $2.2M, 0.46% of portfolio, New
  2. 2025 Q3: 41,226 shares, $2.7M, 0.49% of portfolio, Reduce −7.6%
  3. 2025 Q4: 41,226 shares, $2.2M, 0.30% of portfolio
  4. 2026 Q1: 39,605 shares, $1.9M, 0.29% of portfolio, Reduce −3.9%
  5. 2026 Q2: 39,605 shares, $2.2M, 0.30% of portfolio
Holdings date Value % of holdings Shares Filing date All 13F holders